Australia's most trusted
source of pharma news
Wednesday, 10 December 2025
Posted 9 December 2025 PM
Scrutiny of two Federal Government vaccine deals with Seqirus and Moderna to secure Australia's onshore manufacturing capability and supply has uncovered serious flaws.
According to a report by the Australian National Audit office (ANAO) released yesterday, a billion-dollar deal struck between the Commonwealth and Seqirus in 2020 did not maximise value for money for Australian taxpayers.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.